Azelis stock faces Jefferies downgrade as leverage limits recovery

Jefferies downgraded Azelis from Buy to Hold on Wednesday, November 11, 2026, and reduced its price target to 13 euros from 15 euros. Investing.com reported that analyst David Kerstens sees a recovery toward moderate, volume-driven growth and gradually improving margins as largely reflected in the shares after their recent advance.

Azelis stock traded at 11.95 euros on Lang & Schwarz at 10:09 CET on Friday, November 13, 2026.

Growth Improves In The Third Quarter

The cautious broker view followed a stronger underlying third quarter. According to Azelis' Q3 2026 results, revenue rose 8.5 percent in constant currency to 1.122 billion euros, including organic growth of 8.2 percent. Adjusted EBITA increased 14.6 percent to 114 million euros, while the adjusted EBITA margin expanded to 10.2 percent from 9.7 percent a year earlier.

Industrial Chemicals provided a substantial part of the momentum, with quarterly revenue growth of 21.0 percent on an organic basis. Asia Pacific also reported strong development, while parts of Life Sciences remained more challenging. Group gross margin edged up to 23.4 percent from 23.3 percent in the prior-year quarter.

Cash Flow Keeps Pressure On Valuation

The operating improvement was accompanied by weaker cash conversion. Free cash flow fell 52.5 percent year on year to 67 million euros in the quarter, reducing the free cash flow conversion ratio to 58.6 percent from 142.7 percent. Azelis attributed the pressure to higher working-capital requirements as inventory increased to support recovering demand.

Net debt stood at 1.6 billion euros at the end of September, with leverage at 3.46 times EBITDA. That remains above management's target of below three times EBITDA and helps explain why the broker places greater weight on cash generation and balance-sheet repair. Azelis also recognized a 350 million euro non-cash goodwill impairment, mainly related to past acquisitions in the Americas. The charge reduced reported earnings and equity but did not directly affect cash flow, working capital or net debt.

Guidance Remains Unchanged

Management continued to target positive organic adjusted EBITA growth for the full year 2026. The company also retained medium-term ambitions for high-single-digit annual adjusted EBITA growth, a doubling of earnings per share by 2031 and a return on capital employed above 11.5 percent.

Jefferies expects a 6 percent EBITA recovery and raised its cost-of-capital assumption to 10 percent from 9 percent when setting the lower target. Investing.com said the brokerage expects the specialty-distribution sector to benefit from gradually normalizing industry conditions, but sees the fading inflation tailwind and a market still waiting for clearer volume growth.

The immediate investor test is whether stronger demand can translate into more efficient working-capital use and lower leverage. Azelis also indicated that it does not expect to complete acquisitions in 2026 while leverage and acquisition prices remain high.

For broader market context, investors can follow the Euro Stoxx 50.

Further company-specific developments, including results and broker assessments, are available in More news and analyses on Azelis stock.